Spyre Therapeutics: Paradigm BioCapital reports 5.1% stake
Paradigm BioCapital Advisors LP and related entities reported a 5.1% stake in Spyre Therapeutics (SYRE), owning 4,457,450 shares as of September 24, 2026. The Fund also owns 3,928,646 shares (4.5%). The percentages are based on 88,173,762 shares outstanding as of July 28, 2026.
How this was made
The 30-second read
Why it matters
The filing is a routine disclosure of ownership, offering limited new information beyond the stake size.
Market read
Provides a modest data point for investors monitoring Spyre's shareholder base; unlikely to move the stock significantly.
What to watch
Potential hidden relationships between Paradigm BioCapital and Spyre's pipeline or upcoming financing rounds.
Background
A Schedule 13G filing reports that Paradigm BioCapital Advisors and its related entities own 5.1% of Spyre Therapeutics, a micro‑cap biotech.
Ticker impact
Paradigm BioCapital disclosed a 5.1% beneficial ownership stake in Spyre Therapeutics via a Schedule 13G filing.
potential pressure as the market prices in the larger ownership position
A 5% stake is notable for a micro‑cap biotech, but the filing is routine and does not indicate an immediate corporate action.
Market effects
Minor; may draw attention to the biotech sector but no direct sector shift.
Limited to U.S. investors tracking micro‑cap biotech stocks.
Low; the filing is company‑specific with no broader macro impact.
Counterpoint
The stake could be a strategic foothold for future activism, suggesting upside if the investor pushes for value‑creating actions.
Key entities
- companySpyre Therapeutics, Inc.
Biotech firm whose shares are the subject of the 13G filing.
- investment_firmParadigm BioCapital Advisors LP
Entity reporting the beneficial ownership stake.
